Cargando…

N-Terminal Pfs230 Domain Produced in Baculovirus as a Biological Active Transmission-Blocking Vaccine Candidate

Transmission-blocking vaccines have the potential to accelerate malaria parasite elimination by inducing antibodies that block parasite transmission from humans to mosquitoes. Pfs230, a gametocyte surface protein involved in gamete function, has long been a promising candidate. Due to the large size...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Shwu-Maan, Wu, Chia-Kuei, Plieskatt, Jordan L., Miura, Kazutoyo, Hickey, John M., King, C. Richter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2017
Materias:	Vaccines
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629673/ https://www.ncbi.nlm.nih.gov/pubmed/28747311 http://dx.doi.org/10.1128/CVI.00140-17

Ejemplares similares

The Pfs230 N-terminal fragment, Pfs230D1+: expression and characterization of a potential malaria transmission-blocking vaccine candidate
por: Lee, Shwu-Maan, et al.
Publicado: (2019)

A C-terminal Pfs48/45 malaria transmission-blocking vaccine candidate produced in the baculovirus expression system
por: Lee, Shwu-Maan, et al.
Publicado: (2020)

Expression and purification optimization of an N-terminal Pfs230 transmission-blocking vaccine candidate
por: Lee, Shwu-Maan, et al.
Publicado: (2019)

Assessment of Pfs25 expressed from multiple soluble expression platforms for use as transmission-blocking vaccine candidates
por: Lee, Shwu-Maan, et al.
Publicado: (2016)

Peptide data on the disulfide bond analysis of baculovirus produced Pfs25 by LC-MSMS
por: Lee, Shwu-Maan, et al.
Publicado: (2018)

Development and Qualification of an Antigen Integrity Assay for a Plasmodium falciparum Malaria Transmission Blocking Vaccine Candidate, Pfs230
por: Miura, Kazutoyo, et al.
Publicado: (2022)

Disulfide bond mapping of Pfs25, a recombinant malaria transmission blocking vaccine candidate
por: Lee, Shwu-Maan, et al.
Publicado: (2018)

Identification of domains within Pfs230 that elicit transmission blocking antibody responses
por: Tachibana, Mayumi, et al.
Publicado: (2019)

Elucidating functional epitopes within the N-terminal region of malaria transmission blocking vaccine antigen Pfs230
por: Miura, Kazutoyo, et al.
Publicado: (2022)

Preclinical development of a Pfs230-Pfs48/45 chimeric malaria transmission-blocking vaccine
por: Singh, Susheel K., et al.
Publicado: (2021)

Vaccine co-display of CSP and Pfs230 on liposomes targeting two Plasmodium falciparum differentiation stages
por: Huang, Wei-Chiao, et al.
Publicado: (2022)

Antibody response of a particle-inducing, liposome vaccine adjuvant admixed with a Pfs230 fragment
por: Huang, Wei-Chiao, et al.
Publicado: (2020)

Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48/45 proteins
por: Singh, Kavita, et al.
Publicado: (2020)

Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose
por: Huang, Wei-Chiao, et al.
Publicado: (2020)

Nanobodies against Pfs230 block Plasmodium falciparum transmission
por: Dietrich, Melanie H., et al.
Publicado: (2022)

Pfs230 yields higher malaria transmission–blocking vaccine activity than Pfs25 in humans but not mice
por: Healy, Sara A., et al.
Publicado: (2021)

Potent transmission-blocking monoclonal antibodies from naturally exposed individuals target a conserved epitope on Plasmodium falciparum Pfs230
por: Ivanochko, Danton, et al.
Publicado: (2023)

Pfs230 and Pfs48/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium falciparum
por: Singh, Susheel K., et al.
Publicado: (2019)

A potent and durable malaria transmission-blocking vaccine designed from a single-component 60-copy Pfs230D1 nanoparticle
por: Salinas, Nichole D., et al.
Publicado: (2023)

A Plant-Produced in vivo deglycosylated full-length Pfs48/45 as a Transmission-Blocking Vaccine Candidate against malaria
por: Mamedov, Tarlan, et al.
Publicado: (2019)

Outer membrane protein complex as a carrier for malaria transmission blocking antigen Pfs230
por: Scaria, Puthupparampil V., et al.
Publicado: (2019)

Structure of the malaria vaccine candidate Pfs48/45 and its recognition by transmission blocking antibodies
por: Ko, Kuang-Ting, et al.
Publicado: (2022)

Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer
por: Miura, Kazutoyo, et al.
Publicado: (2007)

Structural delineation of potent transmission-blocking epitope I on malaria antigen Pfs48/45
por: Kundu, Prasun, et al.
Publicado: (2018)

Structural basis for recognition of the malaria vaccine candidate Pfs48/45 by a transmission blocking antibody
por: Lennartz, Frank, et al.
Publicado: (2018)

Rare Alleles and Signatures of Selection on the Immunodominant Domains of Pfs230 and Pfs48/45 in Malaria Parasites From Western Kenya
por: Ochwedo, Kevin O., et al.
Publicado: (2022)

Preclinical evaluations of Pfs25-EPA and Pfs230D1-EPA in AS01 for a vaccine to reduce malaria transmission
por: Rausch, Kelly M., et al.
Publicado: (2023)

Clinical Trial of an Oral Live Shigella sonnei Vaccine Candidate, WRSS1, in Thai Adults
por: Pitisuttithum, Punnee, et al.
Publicado: (2016)

Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25
por: Scally, Stephen W., et al.
Publicado: (2017)

Antibody responses to two new Lactococcus lactis-produced recombinant Pfs48/45 and Pfs230 proteins increase with age in malaria patients living in the Central Region of Ghana
por: Acquah, Festus K., et al.
Publicado: (2017)

Poor CD4(+) T Cell Immunogenicity Limits Humoral Immunity to P. falciparum Transmission-Blocking Candidate Pfs25 in Humans
por: Zaric, Marija, et al.
Publicado: (2021)

Process of Assay Selection and Optimization for the Study of Case and Control Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine, MVA85A
por: Harris, Stephanie A., et al.
Publicado: (2014)

Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study
por: Riddle, Mark S., et al.
Publicado: (2016)

Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51
por: Wu, Yimin, et al.
Publicado: (2008)

The Dynamics of Naturally Acquired Immune Responses to Plasmodium falciparum Sexual Stage Antigens Pfs230 & Pfs48/45 in a Low Endemic Area in Tanzania
por: Bousema, Teun, et al.
Publicado: (2010)

Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice
por: Coelho, Camila H., et al.
Publicado: (2019)

Plant-produced transmission blocking Plasmodium falciparum Pfs25 subunit and VLP based vaccine candidates
por: Musivchuk, Konstantin, et al.
Publicado: (2012)

A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based Plasmodium falciparum Transmission-Blocking Vaccine
por: Singh, Susheel K., et al.
Publicado: (2021)

Characterization and Vaccine Potential of Membrane Vesicles Produced by Francisella noatunensis subsp. orientalis in an Adult Zebrafish Model
por: Lagos, Leidy, et al.
Publicado: (2017)

Malaria Derived Glycosylphosphatidylinositol Anchor Enhances Anti-Pfs25 Functional Antibodies That Block Malaria Transmission
por: Kapoor, Neeraj, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h4dag42tq5ta42lb9o49t8jhms